Fifth Eye uses continuous physiologic waveforms to build clinical early warning systems that enable proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay and reduce healthcare costs. The financing will be used to secure FDA clearance of Fifth Eye’s first product, support clinical studies with multiple health systems, and enable commercial launch of the company’s first product, the Analytic for Hemodynamic Instability.
